obecabtagene autoleucel
AXP000019.1 · CAR-T cell therapy
- Platform
- autologous CAR-T
- Targets
- CD19
- Originator
- Autolus Therapeutics
- Sponsor
- Autolus Therapeutics
Names
| Name | Type | Source |
|---|---|---|
| obecabtagene autoleucel | preferred name, INN | curator, ncit |
| Aucatzyl | brand | ncit |
| AUTO1 | code | ncit |
| obe-cel | synonym | ncit |
Virus
- Role
- Ex vivo gene transfer
- Family
- Retroviridae
- Virus
- lentivirus
- Replication
- non replicating
- Modifications
- replication-incompetent lentiviral vector containing the CD19 CAR transgene; murine anti-CD19 scFv with 4-1BB costimulatory and CD3 zeta signalling domains
- Transgenes
- anti-CD19 chimeric antigen receptor
- Route
- ex vivo, intravenous
- Carrier
- autologous T cells
- Source
- evidence
Cross-references
- NCI Thesaurus
- C172746
- Wikidata
- Q131314725
- FDA UNII
- 760HJB0YRD
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| FDA | US | 2024-11-08 | approved | Aucatzyl | Adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia | source |
| EMA | EU | 2025-07-17 | conditional | Aucatzyl | Adults aged 26 and over with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia | source |
Clinical trials (8)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07400029 | A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia | Recruiting | Phase 2 | 2026-02-03 | 2029-02 | 40 | Acute Lymphoblastic Leukemia |
| NCT07053800 | Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) | Recruiting | Phase 2 | 2026-01-16 | 2028-08 | 35 | Lupus Nephritis |
| NCT07053059 | Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL) | Recruiting | Phase 2 | 2025-08-26 | 2028-05-31 | 30 | Acute Lymphocytic Leukemia (ALL) |
| NCT07139743 | Obe-cel in Refractory Progressive Forms of Multiple Sclerosis | Recruiting | Phase 1 | 2025-08-04 | 2029-08-15 | 24 | Progressive Multiple Sclerosis |
| NCT06333483 | Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus | Active not recruiting | Phase 1 | 2024-02-02 | 2027-09 | 16 | Systemic Lupus Erythematosus |
| NCT06173518 | A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) | Recruiting | Phase 1 | 2023-11-16 | 2027-11 | 30 | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia; Relapsed or Refractory B Cell Non-Hodgkin Lymphoma |
| NCT04404660 | A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) | Active not recruiting | Phase 1/2 | 2020-06-03 | 2029-06-30 | 153 | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia |
| NCT06799221 | Expanded Access Program for OOS Obe-cel | Available | B Cell ALL; Lymphoblastic Leukemia, Acute, Adult |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41504229 | Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. | Haematologica | 2026 | cited by trial NCT04404660 |
| PMID 42241689 | CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study. | Cancer research communications | 2026 | name in title: obecabtagene autoleucel |
| PMID 42469475 | Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. | Leukemia | 2026 | name in title: obecabtagene autoleucel |
| PMID 41671463 | Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. | Journal of the National Comprehensive Cancer Network : JNCCN | 2025 | cited by trial NCT06173518 |
| PMID 39602653 | Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. | The New England journal of medicine | 2024 | cited by trial NCT04404660 |
Unconfirmed matches (2)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 34464155 | Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021 | name in abstract: AUTO1 |
| PMID 12679622 | Immunologic effects of allogeneic versus autologous blood transfusion in patients undergoing radical oesophagectomy. | European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes | 2003 | name in abstract: AUTO1 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41826187 | [Obecabtagene autoleucel (Obe-cel) in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia]. | Bulletin du cancer | 2026 | name in title: obecabtagene autoleucel |
| PMID 42373851 | False-positive HIV-1 RNA detection following obecabtagene autoleucel. | Bone marrow transplantation | 2026 | name in title: obecabtagene autoleucel |
| PMID 42381271 | Immune effector cell-associated hematotoxicity following CAR-T cell therapies: insights from a large national database. | Japanese journal of clinical oncology | 2026 | name in abstract: obecabtagene autoleucel |
| PMID 42572849 | Obecabtagene Autoleucel in Relapsed/Refractory B-ALL: A Critical Review of Clinical Efficacy and Safety. | The Annals of pharmacotherapy | 2026 | name in title: obecabtagene autoleucel |
| PMID 42609184 | Erratum to: "Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia". | Haematologica | 2026 | name in title: obecabtagene autoleucel |
| PMID 39791458 | Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy. | Leukemia & lymphoma | 2025 | name in abstract: obecabtagene autoleucel |
| PMID 39888581 | Obecabtagene Autoleucel: First Approval. | Molecular diagnosis & therapy | 2025 | name in title: obecabtagene autoleucel |
| PMID 39928344 | Obecabtagene Autoleucel for B-Cell Acute Lymphoblastic Leukemia. | JAMA | 2025 | name in title: obecabtagene autoleucel |
| PMID 39930262 | Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALL. | Nature reviews. Clinical oncology | 2025 | name in title: obecabtagene autoleucel |
| PMID 39954668 | Always more immunotherapy in the management of B-lineage acute lymphoblastic leukemia. | Med (New York, N.Y.) | 2025 | name in abstract: obecabtagene autoleucel |
| PMID 39954962 | Awakening from REMS: ASTCT 80/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T Cells. | Transplantation and cellular therapy | 2025 | name in abstract: obecabtagene autoleucel |
| PMID 40550480 | Obecabtagene autoleucel, a novel CD19-directed CAR T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: the future for reducing toxicity and T-cell exhaustion? | Expert review of hematology | 2025 | name in title: obecabtagene autoleucel |
| PMID 40550595 | An interview with Dr. Jean A. Yared on his experience as an investigator for obecabtagene autoleucel - by Reegan Burnell-Clarke (Commissioning Editor). | Expert review of hematology | 2025 | name in title: obecabtagene autoleucel |
| PMID 41201546 | Transforming the Treatment of Acute Lymphoblastic Leukemia: the Role of Bispecific Antibodies, Antibody-Drug Conjugates, and CAR T-cell Therapy. | Current hematologic malignancy reports | 2025 | name in abstract: obecabtagene autoleucel |
| PMID 39559248 | Clinical Insights on Brexucabtagene Autoleucel for the Treatment of Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. | Cancer management and research | 2024 | name in abstract: obecabtagene autoleucel |
| PMID 39762192 | In brief: Obecabtagene autoleucel (Aucatzyl) - another CAR-T cell immunotherapy for ALL. | The Medical letter on drugs and therapeutics | 2024 | name in title: obecabtagene autoleucel |
| PMID 36945773 | Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR. | Molecular therapy : the journal of the American Society of Gene Therapy | 2023 | name in abstract: obe-cel |
| PMID 37709295 | AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival. | Journal for immunotherapy of cancer | 2023 | name in title: AUTO1 |
Unconfirmed matches (5)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42665916 | Real-world clinical impact of implementing and updating a deep learning-based automatic contouring system in rectal cancer radiotherapy. | Journal of applied clinical medical physics | 2026 | name in abstract: AUTO1 |
| PMID 37647647 | CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL. | Blood | 2024 | name in abstract: AUTO1 |
| PMID 39341137 | Protective role of ghrelin against 6PPD-quinone-induced neurotoxicity in zebrafish larvae (Danio rerio) via the GHSR pathway. | Ecotoxicology and environmental safety | 2024 | name in abstract: AUTO1 |
| PMID 21780236 | Fully automatic geometry planning for cardiac MR imaging and reproducibility of functional cardiac parameters. | Journal of magnetic resonance imaging : JMRI | 2011 | name in abstract: AUTO1 |
| PMID 8557329 | A patient-derived cytotoxic T-lymphocyte clone and two peptide-dependent monoclonal antibodies recognize HLA-B27-peptide complexes with low stringency for peptide sequences. | Infection and immunity | 1996 | name in abstract: AUTO1 |
Notes
Fast-off-rate anti-CD19 (CAT19) 4-1BB CAR from UCL (Pule lab), developed by UCL spin-out Autolus.
How to cite
obecabtagene autoleucel (AXP000019.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000019.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.